The cost of GLP-1s needs to come way down for benefits to be worth it, study saysByBruce GilPublishedMarch 17, 2025
The weight loss drug shortage is over — and some patients are 'panicking'ByBruce GilPublishedMarch 17, 2025
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundupByBruce GilPublishedMarch 14, 2025
Lawmakers demand answers from RFK Jr. over Trump dinners with pharma execsByBruce GilPublishedMarch 11, 2025
Viking Therapeutics closer to bringing its Ozempic competitor to marketByBruce GilUpdatedMarch 11, 2025
Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive saysByBruce GilPublishedMarch 10, 2025
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundupByBruce GilPublishedMarch 7, 2025
Big Pharma wants to bring back a tax break that could save it $15 billionByBruce GilPublishedMarch 6, 2025
Now playing Ozempic competitor in the works at Amgen reaches late-stage clinical trialsPublishedMarch 5, 2025
Now playing Amgen just got one step closer to bringing its Ozempic competitor to marketByBruce GilUpdatedMarch 5, 2025
Pfizer CEO says he's prepared to shift manufacturing to the U.S. amid tariff threatsByBruce GilUpdatedMarch 3, 2025
Eli Lilly comes for knockoff weight loss drugs in new ad campaignByBruce GilPublishedFebruary 28, 2025
Eli Lilly's big investment, cheaper Zepbound, and what's next for Hims & Hers: Pharma news roundupByBruce GilPublishedFebruary 28, 2025
Eli Lilly wants to make drugs in America. First it wants a tax cutByBruce GilPublishedFebruary 27, 2025
